To establish efficacy, an antidepressant must show that it can produce a therapeutic effect for the condition for which it is taken. An antidepressant should be more efficacious than placebo to justify the risk associated with side effects. For depression, the Hamilton Depression Rating Scale (HAM-D) is often used to measure the severity of depression. The maximum score for the 17-item HAM-D questionnaire is 52; the higher the score, the more severe the depression. What constitute a sufficient response to a drug has not been well established, but total remission or virtual elimination of all depression symptoms is the goal, however, remission rates are rarely published. For placebo, the percentage of symptom reduction is approximately 31 to 38%, compared to 46 to 54% for antidepressants.
On the basis of 234 studies, no clinically relevant superiority of one antidepressant over another was detected for the treatment of acute, continuation, and maintenance phases of depression, taking into account age, sex, ethnicity, or comorbid conditions. Individual drugs differed in onset of action, adverse events, and some measures of health-related quality of life.
After the first course of treatment, 27.5% of the 2,876 participants reached remission with a HAM-D score of 7 or less. 21% dropped out.
After the second course of treatment, 21 to 30% of the remaining 1,439 participants remitted. Only 310 participants were willing or available to continue the study. Switching medications can achieve remission in about 25% of patients.
After the third course of treatment, 17.8% of the remaining 310 participants remitted.
After the fourth and last course of treatment, 10.1% of the remaining 109 participants remitted.
After a one year follow-up, of the 1085 remitted participants, 93% participants had either relapsed or dropped out of the study.
There were no statistical or meaningful clinical differences in remission rates, response rates, or times to remission or response among any of the medications compared in this study. These included bupropion sustained release, bupropion, citalopram, lithium, mirtazapine, nortriptyline, sertraline, triiodothyronine, tranylcypromine, and venlafaxine extended release.[medical citation needed]
A 2008 review of randomized controlled trials concluded that symptomatic improvement with SSRIs was greatest by the end of the first week of use, but that some improvement continued for at least 6 weeks.
A 2002 review concluded that there was no evidence that antidepressants reduce the risk of recurrence of depression when their use is terminated. The authors of this review advocated that antidepressants be combined with therapy, and pointed to interpersonal psychotherapy (IPT) and cognitive behavioral therapy (CBT).
The UK National Institute for Clinical Excellence (NICE) 2004 guidelines indicate that antidepressants should not be used for the initial treatment of mild depression, because the risk-benefit ratio is poor; that for moderate or severe depression an SSRI is more likely to be tolerated than a tricyclic; and that antidepressants for severe depression should be combined with a psychological treatment such as Cognitive Behavioral Therapy.
The American Psychiatric Association 2000 Practice Guideline for the Treatment of Patients with major depressive disorder indicates that, if preferred by the patient, antidepressant medications may be provided as an initial primary treatment for mild major depressive disorder; antidepressant medications should be provided for moderate to severe major depressive disorder unless electroconvulsive therapy is planned; and a combination of antipsychotic and antidepressant medications or electroconvulsive therapy should be used for psychotic depression. It states that efficacy is generally comparable between classes and within classes and that the initial selection will largely be based on the anticipated side-effects for an individual patient, patient preference, quantity and quality of clinical trial data regarding the medication, and its cost.
Limitations and strategies
Between 30% and 50% of individuals treated with a given antidepressant do not show a response. In clinical studies, approximately one-third of patients achieve a full remission, one-third experience a response and one-third are nonresponders. Partial remission is characterized by the presence of poorly defined residual symptoms. These symptoms typically include depressed mood, psychic anxiety, sleep disturbance, fatigue and diminished interest or pleasure. It is currently unclear which factors predict partial remission. However, it is clear that residual symptoms are powerful predictors of relapse, with relapse rates 3–6 times higher in patients with residual symptoms than in those who experience full remission. In addition, antidepressant drugs tend to lose efficacy over the course of treatment. A number of strategies are used in clinical practice to try to overcome these limits and variations. They include switching medication, augmentation, and combination.
"Trial and error" switching
The American Psychiatric Association 2000 Practice Guideline advises that where no response is achieved following six to eight weeks of treatment with an antidepressant, to switch to an antidepressant in the same class, then to a different class of antidepressant. The remission rate reported by the STAR*D study was 21% using this method.[medical citation needed]
A 2006 meta-analysis review found wide variation in the findings of prior studies; for patients who had failed to respond to an SSRI antidepressant, between 12% and 86% showed a response to a new drug. However, the more antidepressants an individual had already tried, the less likely they were to benefit from a new antidepressant trial. However, a later meta-analysis found no difference between switching to a new drug and staying on the old medication; although 34% of treatment resistant patients responded when switched to the new drug, 40% responded without being switched. Thus, the clinical response to the new drug might be a placebo effect associated with the belief that one is receiving a different medication.[medical citation needed]
A combination strategy involves adding an additional antidepressant, usually from a different class so as to have effect on other mechanisms. Although this may be used in clinical practice, there is little evidence for the relative efficacy or adverse effects of this strategy.
Opponents of switching, augmentation and combination argue that treatment may also propel the illness to a malignant and treatment-unresponsive course with iatrogenic psychiatric-like symptoms and treatment resistance or episode acceleration.
The therapeutic effects of antidepressants typically do not continue once the course of medication ends, resulting in a high rate of relapse. A recent meta-analysis of 31 placebo-controlled antidepressant trials, mostly limited to studies covering a period of one year, found that 18% of patients who had responded to an antidepressant relapsed while still taking it, compared to 41% whose antidepressant was switched for a placebo.
In a five-year follow up, relapse rates was 23% greater for users greater than one year, but not different for 6 or 12 months users. In addition, gradual loss of therapeutic benefit occurs during the course of treatment. A strategy involving the use of pharmacotherapy in the treatment of the acute episode, followed by psychotherapy in its residual phase, has been suggested by some studies.
Another possible problem with antidepressants is the chance of antidepressant-induced mania in patients with bipolar disorder. Many cases of bipolar depression are very similar to those of unipolar depression. Therefore, the patient can be misdiagnosed with unipolar depression and be given antidepressants. Studies have shown that antidepressant-induced mania can occur in 20-40% of bipolar patients.
This section needs more medical references for verification or relies too heavily on primary sources. Please review the contents of the section and add the appropriate references if you can. Unsourced or poorly sourced material may be removed.(November 2013)
Various researchers have contested the ability of antidepressants to relieve depression, skeptical that the drugs aid patients significantly more than placebo.
A review of antidepressant trials submitted to the FDA by the industry for drug approval revealed that when a trial was successful, the results of the trial was published 94% of the time, however, when the trial was not found to be more effective than placebo, it was only published 50% of the time. This demonstrated a measure of bias in reporting by industry. Combined, 51% of all studies showed efficacy. The difference in effect between active placebos and several antidepressants appeared small and strongly affected by publication bias.
Controversy regarding the efficacy of antidepressants has arisen due to studies showing that antidepressants fail to provide significantly greater efficacy than placebo in some studies. A 2002 study claimed that the difference between antidepressants and placebo is close to negligible.
A meta-analysis done by two psychologists led them to believe that although the drugs did help people, the difference between the pills and placebo was not meaningful for patients; a later publication by the same author concluded newer-generation medicines were below the criteria of clinical significance.
A study published in the Journal of the American Medical Association (JAMA) demonstrated that the magnitude of the placebo effect in clinical trials of depression have been growing over time, while the effect size of tested drugs has remained relatively constant. The authors suggest that one possible explanation for the growing placebo effect in clinical trials is the inclusion of larger number of participants with shorter term, mild, or spontaneously remitting depression as a result of decreasing stigma associated with antidepressant use. Another study focusing on paroxetine (Paxil) and imipramine found that antidepressant drugs were hardly better than placebo in cases of mild or moderate depression they surveyed.
The Cochrane Collaboration recently performed a systematic review of clinical trials of the generic antidepressant amitriptyline. The study concluded that in spite of moderate evidence for publication bias, there is strong evidence that the efficacy of amitriptyline is superior to placebo.
A review commissioned by the National Institute for Clinical Excellence concluded that there there is strong evidence that SSRIs have greater efficacy than placebo on achieving a 50% reduction in depression scores in moderate and severe major depression, and that there is some evidence for a similar effect in mild depression. The treatment guidelines developed in conjunction with this review suggest that antidepressants should be considered in patients with moderate to severe depression and those with mild depression that is persistent or resistant to other treatment modalities.
In 2005, antidepressants became the most prescribed drug in the United States, causing more debate over the issue. Some doctors believe this is a positive sign that people are finally seeking help for their issues. Others disagree, saying that this shows that people are becoming too dependent on antidepressants.
In 2012, Aimee Hunter and her team used electroencephalography (EEG) and showed that taking placebo decreased pre-frontal brain activity in those subjects who had prior use of an antidepressants, similar to the expected antidepressant response, but increased brain activity in antidepressant-naive subjects. She attributes this antidepressant response of placebo, in repeat users, to a memory effect.
However, the later experiment conducted by John H. Krystal at Yale University School of Medicine to assess whether growth mixture modeling can provide insights into antidepressant and placebo responses in clinical trials of patients with major depression showed that Duloxetine and SSRI did not differ in efficacy, and compared with placebo they significantly decreased the odds of following the nonresponder trajectory. Antidepressant responders had significantly better Hamilton Depression Rating Scale (HAM-D) scores over time than placebo-treated patients, but antidepressant nonresponders had significantly worse HAM-D scores over time than the placebo-treated patients.
4 extremely tolerable. These drugs have proven to be better tolerated than the SSRIs.
3 very tolerable ? few, mild and transient side effects. These are drugs such as the SSRIs.
2 moderately tolerable. Some of the more tolerable of TCAs.
1 poor tolerability. TCAs and MAOIs mostly.
3 Superior efficacy drug, according to at least one review article.
2 Ordinary efficacy drug. Maybe some primary sources indicate superior efficacy relative to superior efficacy agents (e.g. agomelatine has shown superior efficacy to venlafaxine in one clinical trial) but insufficient data to say with much confidence.
1 Inferior efficacy compared to ordinary efficacy drugs, according to at least one review article.
Acronyms/terms used in the above table:
Activating effects - adverse effects such as agitation, anxiety, insomnia and tremor.
Moclobemide: Only clinically utilized reversible inhibitor of monoamine oxidase A (RIMA). Not approved for use in the US. Approved for clinical use in Australia, Canada, Ireland, New Zealand, Singapore, South Africa and the UK. Activating effects: ? (insomnia common according to the AMH)
Phenelzine: Phenelzine and tranylcypromine can both cause liver damage.
Seligiline: Originally used a treatment for Parkinson's disease due to its selective, irreversible inhibition of MAO-B but at higher doses MAO-A inhibition occurs.
Citalopram: Most likely of the SSRIs to prolong the QT interval. Also the most toxic SSRI in overdose. QTc i. p.: 2 (dose dependent; doses >40 mg/day are particularly dangerous)
Escitalopram: The more active S-enantiomer of citalopram. May be the most efficacious of the SSRIs (although no statistically significant difference between the efficacy of sertraline and escitalopram have been teased out to date). Based on the available evidence it is less toxic than its racemic counterpart, (R,S)-citalopram, in overdose.
Fluoxetine: First SSRI to receive FDA approval in 1987. Some studies have shown slight (often statistically insignificant) weight reductions in those on fluoxetine. Has the longest net half-life (taking into account the effects of its active metabolite, norfluoxetine) of any antidepressant clinically used, and consequently, when abruptly stopped, withdrawal effects are usually mild and rare. Dermatologic reactions are more common than with sertraline.
Paroxetine: Only SSRI that's not Australian pregnancy category C but is rather category D due to an increased risk of Persistent Pulmonary Hypertension of the Newborn. The FDA of the US has placed it in category D. It is associated with a higher risk of sexual dysfunction, weight gain, anticholinergic side effects and drowsiness than the other SSRIs. Has a short half life compared to other SSRIs and hence is the most prone to causing withdrawal effects whenever a dose is missed. Paroxetine has the lowest affinity for the sigma-1 receptors of all the SSRIs. It also possesses the highest propensity of any SSRI for causing extrapyramidal symptoms.
Sertraline: Highest risk of psychiatric side effects (e.g. mania, suicidal behavior/ideation, psychosis, etc.) Has slight (but clinically significant) inhibitory effects on dopamine reuptake. Has the second highest affinity of the SSRIs towards the sigma-1 receptor where it may serve as a sigma-1 receptor antagonist. GI toxicity: 2 (mostly diarrhoea)
Mianserin: Not licensed for use in the US and Canada. Licensed for use in Australia and the UK. Can cause blood dyscrasias (including agranulocytosis) and consequently both the BNF and AMH recommend regular complete blood count monitoring.
Mirtazapine: Licensed for use in the US, UK, Australia and Canada. Mianserin's successor and analogue.
For bipolar depression, antidepressants (most frequently SSRIs) can exacerbate or trigger symptoms of hypomania and mania.
Almost any medication involved with serotonin regulation has the potential to cause serotonin toxicity (also known as serotonin syndrome) – an excess of serotonin that can induce mania, restlessness, agitation, emotional lability, insomnia and confusion as its primary symptoms. Although the condition is serious, it is not particularly common, generally only appearing at high doses or while on other medications. Assuming proper medical intervention has been taken (within about 24 hours) it is rarely fatal.
MAOIs tend to have pronounced (sometimes fatal) interactions with a wide variety of medications and over-the-counter drugs. If taken with foods that contain very high levels of tyramine (e.g., mature cheese, cured meats, or yeast extracts), they may cause a potentially lethal hypertensive crisis. At lower doses the person may be bothered by only a headache due to an increase in blood pressure.
In response to these adverse effects, a different type of MAOI has been developed: the reversible inhibitor of monoamine oxidase A (RIMA) class of drugs. Their primary advantage is that they do not require the person to follow a special diet, while being purportedly effective as SSRIs and tricyclics in treating depressive disorders.
Pregnancy can trigger a range of emotions that make it more difficult to cope with depression. The risk of medication discontinuation and relapse have to be weighed against the risk to the developing fetus and baby. Some antidepressants have lower risk for the baby during pregnancy, but the FDA advises for the risk of birth defects with the use of Paxil and the MAOI should be avoided. A neonate (infant less than 28 days old) may experience a withdrawal syndrome from abrupt discontinuation of the antidepressant at birth. The use of antidepressants during pregnancy is associated with an increased risk of spontaneous abortion, birth defects, and developmental delays. Antidepressants have been shown to be present in varying amounts in breast milk, but their effects on infants are currently unknown.
Moreover, SSRIs inhibit nitric oxide synthesis, which leads to vasoconstriction. This is significant in pregnancy as SSRIs have been associated with the development of hypertension (high blood pressure) and pre-eclampsia of pregnancy. This in turn can lead to fetal prematurity.
The relationship between antidepressant use and suicide risk is uncertain, complicated, and the target of medical research. Some studies have shown that the use of some antidepressants correlate with an increased risk of suicide in some patients and especially youth. This problem has been serious enough to warrant government interventions in some places to label greater likelihood of suicide as a risk of using antidepressants. The circumstances under which this can happen are not clear, and other studies show that antidepressants treat suicidal ideation.
In a study of 1022 outpatients, overall sexual dysfunction with all antidepressants averaged 59.1% with SSRIs values between 57 and 73%, mirtazapine 24%, nefazodone 8%, amineptine 7% and moclobemide 4%. Moclobemide, a selective reversible MAO-A inhibitor, does not cause sexual dysfunction, and can actually lead to an improvement in all aspects of sexual function.
Bupropion, a weak NDRI and nicotinic antagonist, may be useful in treating reduced libido as a result of SSRI treatment. However, these results are preliminary, and as such must be taken cum grano salis.
All major antidepressant drugs – except trimipramine, bupropion,mirtazapine, and nefazodone – suppress REM sleep, and it has been proposed that the clinical efficacy of these drugs largely derives from their suppressant effects on REM sleep. The three major classes of antidepressant drugs (MAOIs, TCAs, and SSRIs), profoundly suppress REM sleep. Mirtazapine either has no effect on REM sleep or increases it slightly. The MAOIs almost completely suppress REM sleep, while the TCAs and SSRIs have been shown to produce immediate (40-85%) and sustained (30-50%) reductions in REM sleep. This effect often causes increased fatigue in patients who take large doses of antidepressants for extended periods of time. Such fatigue can occasionally interfere with a patient's everyday activities. Abrupt discontinuation of MAOIs can cause a temporary phenomenon known as "REM rebound" in which the patient experiences extremely vivid dreams and nightmares.
Changes in weight
Changes in appetite or weight are common among antidepressants, but largely drug-dependent and are related to which neurotransmitters they affect. Mirtazapine and paroxetine, for example, have the effect of weight gain and/or increased appetite, while others (such as bupropion and venlafaxine) achieve the opposite effect.
The antihistaminic properties of certain TCA- and TeCA-class antidepressants have been shown to contribute to the common side-effects of increased appetite and weight gain associated with these classes of medication.
Withdrawal syndromes have been reported with TCAs, MOAIs, SNRIs, and with SSRIs. Researchers from the Nordic Cochrane Center in Denmark compared the signs and symptoms of SSRI discontinuation to those of the benzodiazepine withdrawal syndrome and concluded that the withdrawal reactions were so similar that both withdrawal reactions indicated a dependence syndrome. Elsewhere, concerns have been raised that SSRIs cause dependence.
When treatment is prolonged over 6–9 months, processes oppose the initial effects of antidepressant drugs (loss of clinical effects). When drug treatment ends, these processes may be unopposed and yield withdrawal symptoms and increased vulnerability to relapse. Such processes are not necessarily reversible. The more antidepressants are switched or potentiated, the more likely oppositional tolerance can take place.
Some of the withdrawal symptoms of SSRI discontinuation include: nausea, chills, muscles aches, dizziness, anxiety, irritability, insomnia, fatigue, and, in some patients, electric shock sensations.
Moreover, when changes in antidepressant dosage occur, whether up or down, a doubling of the risk of suicide is seen.
To minimize the intensity of withdrawal and rebound effects antidepressants should be discontinued over a period of several weeks or months depending on a person's response to reductions. A suggested regimen is a decrease in the SSRI by about 25% per week. This is a guideline; the actual amount of time required to withdraw from a given antidepressant is unique to the drug. Certain antidepressants may have long half-lives and remain in the person's system for a period of time long enough to prevent a sudden "drop" in concentration, meaning that withdrawal or rebound effects are unlikely or less pronounced.
Most cases of discontinuation syndrome last between one and four weeks but a substantial minority, perhaps up to 15% of users, have persistent withdrawal symptoms evident one year post-withdrawal. Paroxetine and venlafaxine seem to be particular difficult to discontinue and prolonged withdrawal syndrome lasting over 18 months have been reported with paroxetine. Peer-support groups exist to help patients taper off of their antidepressants.
The earliest and probably most widely accepted scientific theory of antidepressant action is the monoamine hypothesis (which can be traced back to the 1950s), which states that depression is due to an imbalance (most often a deficiency) of the monoamine neurotransmitters (namely serotonin, norepinephrine and dopamine). It was originally proposed based on the observation that certain hydrazine anti-tuberculosis agents produce antidepressant effects, which was later linked to their inhibitory effects on monoamine oxidase, the enzyme that catalyses the breakdown of the monoamine neurotransmitters. All currently marketed antidepressants have the monoamine hypothesis as their theoretical basis, with the possible exception of agomelatine which acts on a dual melatonergic-serotonergic pathway. Despite the success of the monoamine hypothesis it has a number of limitations: for one, all monoaminergic antidepressants have a delayed onset of action of at least a week; and secondly, there are a sizeable portion (>40%) of depressed patients that do not adequately respond to monoaminergic antidepressants. Further evidence to the contrary of the monoamine hypothesis are the recent findings that a single intravenous infusion with ketamine, an antagonist of the NMDA receptor — a type of glutamate receptor — produces rapid (within 2 hours), robust and sustained (lasting for up to a fortnight) antidepressant effects. To overcome these flaws with the monoamine hypothesis a number of alternative hypotheses have been proposed, including the glutamate, neurogenic, epigenetic, cortisol hypersecretion and inflammatory hypotheses.
Adjunct medications are an umbrella term used to describe substances that increase the potency or "enhance" antidepressants. They work by affecting variables very close to the antidepressant, sometimes affecting a completely different mechanism of action. This is may be attempted when depression treatments have not been successful in the past.
Types of adjunct medication techniques generally fall into the following categories:
Two or more antidepressants taken together
From the same class (affecting the same area of the brain, often at a much higher level)
From different classes (affecting multiple parts of the brain not covered simultaneously by either drug alone)
A stimulant with an antidepressant (e.g., amphetamine and fluoxetine)
A review article published in 2007 found psychostimulants may be effective in treatment-resistant depression with concomitant antidepressant therapy. A more certain conclusion could not be drawn due to substantial deficiencies in the studies available for consideration, and the somewhat contradictory nature of their results.
Chronic nicotine intake via nicotine patches results in an increased response to standard antidepressants. Similarly varenicline has been shown to augment sub-therapeutic doses of SSRIs to produce an antidepressant effect.
Nicotine is believed to act as an antidepressant, by stimulating the release of dopamine and norepinephrine; in addition, nicotine is believed to exert an antidepressant effect due to the desensitisation of nicotinic receptors, which occurs as a result of tolerance. Clinical trials have demonstrated nicotine (administered using a dermal nicotine patch) exerts an antidepressant effect in both depressed nonsmokers and smokers, and can be considered for treatment-resistant depression. The proposed mechanism of chronic nicotine use causing desensitisation of nicotinic receptors – thereby leading to an antidepressant effect – is consistent with the theory first proposed over 30 years ago and subsequent research that confirmed excessive acetylcholine activity in the brain leads to depressive symptoms. Varenicline, a nicotinic receptor-acting drug used to wean people off of nicotine dependence, has also demonstrated antidepressant properties.
Individuals using caffeine at moderate doses (fewer than 6 cups of coffee per day), have a reduced incidence of depressive symptoms and an overall reduced risk of suicide. Anxiety is an important side-effect of caffeine that occurs more commonly in individuals suffering from panic disorder or social phobia or when taken in excessive amounts.
Early studies have shown that ketamine may be effective in treatment-resistant depression, though experts have stated that it is not yet ready for clinical practice but rather may lead to the development of novel medications in the future. It produces a rapid antidepressant effect, acting within two hours as opposed to the several weeks taken by typical antidepressants to work.
Some research has attributed the effect to ketamine being an NMDAreceptor antagonist, though others have suggested that blocking the NMDA receptor is an intermediate step that increases the activity of another receptor, AMPA, which is what is responsible for ketamine's rapid antidepressant actions.
Omega-3 fatty acids have been proposed as a treatment for depression, alone or in combination with other treatments. One small pilot study of childhood depression (ages 6–12) suggested omega 3 fatty acids may have therapeutic benefits for treating childhood depression. A 2005 review article that included double-blind studies, randomized control trials, and epidemiological studies linking omega-3 fatty acids consumption and depression found that low fish consumption (the primary source of omega-3 fatty acids) correlated to increased rates of depression. Additionally, case-control and cohort studies of unipolar and postpartum depression indicated low blood levels of omega-3 fatty acids in depressed patients.
A 2008 review of clinical studies of the effectiveness of omega-3 fatty acids on depression has shown somewhat inconsistent results: "Of the evaluated studies, 13 showed a significant positive association between omega-3 and depression, while six studies did not show a relationship between the referred variables." To be read with caution because of limited data, a 2008 Cochrane systematic review found in the one eligible study that omega-3 fatty acids are an effective adjunctive therapy for depressed but not manic symptoms in bipolar disorder. The authors found an "acute need" for more randomized, controlled trials.
Before the 1950s, opioids, amphetamine, and methamphetamine were commonly used as antidepressants. Their use was later restricted due to their addictive nature and side effects. Extracts from the herb St John's wort had been used as a "nerve tonic" to alleviate depression.
Isoniazid, iproniazid, and imipramine
In 1951, Irving Selikoff and Edward Robitzek, working out of Sea View Hospital on Staten Island, began clinical trials on two new anti-tuberculosis agents developed by Hoffman-LaRoche, isoniazid and iproniazid. Only patients with a poor prognosis were initially treated; nevertheless, their condition improved dramatically. Selikoff and Robitzek noted "a subtle general stimulation ... the patients exhibited renewed vigor and indeed this occasionally served to introduce disciplinary problems." The promise of a cure for tuberculosis in the Sea View Hospital trials was excitedly discussed in the mainstream press.
In 1952, learning of the stimulating side effects of isoniazid, the Cincinnati psychiatrist Max Lurie tried it on his patients. In the following year, he and Harry Salzer reported that isoniazid improved depression in two thirds of their patients and coined the term antidepressant to describe its action. A similar incident took place in Paris, where Jean Delay, head of psychiatry at Sainte-Anne Hospital, heard of this effect from his pulmonology colleagues at Cochin Hospital. In 1952 (before Lurie and Salzer), Delay, with the resident Jean-Francois Buisson, reported the positive effect of isoniazid on depressed patients. For reasons unrelated to its efficacy, isoniazid as an antidepressant was soon overshadowed by the more toxic iproniazid, although it remains a mainstay of tuberculosis treatment. The mode of antidepressant action of isoniazid is still unclear. It is speculated that its effect is due to the inhibition of diamine oxidase, coupled with a weak inhibition of monoamine oxidase A.
Selikoff and Robitzek also experimented with another anti-tuberculosis drug, iproniazid; it showed a greater psychostimulant effect, but more pronounced toxicity. Later, Jackson Smith, Gordon Kamman, George Crane, and Frank Ayd, described the psychiatric applications of iproniazid. Ernst Zeller found iproniazid to be a potent monoamine oxidase inhibitor. Nevertheless, iproniazid remained relatively obscure until Nathan Kline, the influential and flamboyant head of research at Rockland State Hospital, began to popularize it in the medical and popular press as a "psychic energizer". Roche put a significant marketing effort behind iproniazid, including promoting its off-label use for depression. Its sales grew until it was recalled in 1961, due to reports of lethal hepatotoxicity.
Attempting to improve the effectiveness of chlorpromazine, Kuhn – in conjunction with the GeigyPharmaceutical Company – discovered the compound "G 22355", later renamed imipramine. Imipramine had a beneficial effect in patients with depression who showed mental and motor retardation. Kuhn described his new compound as a "thymoleptic" "taking hold of the emotions," in contrast with neuroleptics, "taking hold of the nerves" in 1955-56. These gradually became established, resulting in the patent and manufacture in the US in 1951 by Häfliger and SchinderA.
Antidepressants became prescription drugs in the 1950s. It was estimated that no more than 50 to 100 individuals per million suffered from the kind of depression that these new drugs would treat, and pharmaceutical companies were not enthusiastic in marketing for this small market. Sales through the 1960s remained poor compared to the sales of tranquilizers, which were being marketed for different uses. Imipramine remained in common use and numerous successors were introduced. The use of monoamine oxidase inhibitors (MAOI) increased after the development and introduction of "reversible" forms affecting only the MAO-A subtype of inhibitors, making this drug safer to use.
By the 1960s, it was thought that the mode of action of tricyclics was to inhibit norepinephrine reuptake. However, norepinephrine reuptake became associated with stimulating effects. Later tricyclics were thought to affect serotonin as proposed in 1969 by Carlsson and Lindqvist as well as Lapin and Oxenkrug.[medical citation needed]
St John's wort fell out of favor in most countries through the 19th and 20th centuries, except in Germany, where Hypericum extracts were eventually licensed, packaged and prescribed. Small-scale efficacy trials were carried out in the 1970s and 1980s, and attention grew in the 1990s following a meta-analysis. It remains an over-the-counter drug (OTC) supplement in most countries. Research continues to investigate its active component hyperforin, and to further understand its mode of action.
Society and culture
In the United Kingdom, the use of antidepressants increased by 234% in the 10 years up to 2002. In the US a 2005 independent report stated that 11% of women and 5% of men in the non-institutionalized population (2002) take antidepressants. A 1998 survey found that 67% of patients diagnosed with depression were prescribed an antidepressant. A 2007 study suggested that 25% of Americans were overdiagnosed with depression, regardless of any medical intervention. The findings were based on a national survey of 8,098 people.
A 2002 survey found that about 3.5% of all people in France were being prescribed antidepressants, compared to 1.7% in 1992, often for conditions other than depression and often not in line with authorizations or guidelines. Between 1996 and 2004 in British Columbia, antidepressant use increased from 3.4% to 7.2% of the population. Data from 1992 to 2001 from the Netherlands indicated an increasing rate of prescriptions of SSRIs, and an increasing duration of treatment. Surveys indicate that antidepressant use, particularly of SSRIs, has increased rapidly in most developed countries, driven by an increased awareness of depression together with the availability and commercial promotion of new antidepressants. Antidepressants are also increasingly used worldwide for non-depressive patients as studies continue to show the potential of immunomodulatory, analgesic and anti-inflammatory properties in antidepressants.[medical citation needed]
The choice of a particular antidepressant is reported to be based, in the absence of research evidence of differences in efficacy, on seeking to avoid certain side-effects, and taking into account comorbid (co-occurring) psychiatric disorders, specific clinical symptoms and prior treatment history.
It is also reported that, despite equivocal evidence of a significant difference in efficacy between older and newer antidepressants, clinicians perceive the newer drugs, including SSRIs and SNRIs, to be more effective than the older drugs (tricyclics and MAOIs). Currently, the most commonly prescribed antidepressants are selective serotonin reuptake inhibitors (SSRIs), even though a Cochrane systematic review found no major difference in efficacy between SSRIs and tricyclic antidepressants. A survey in the UK found that male general physicians were more likely to prescribe antidepressants than female doctors.
The number of antidepressants prescribed by the National Health Service (NHS) in the UK almost doubled during one decade, authorities reported in 2010. Furthermore the number increased sharply in 2009 when 39.1 million prescriptions were issued, compared to 20.1 million issued in 1999. Also, physicians issued 3.18 million more prescriptions in 2009 than in 2008. Health authorities believed the increase was partly linked to the recession. However, other reasons include a diagnosis improvement, a reduction of the stigma on mental ill-health, and more distress caused by the economic crisis. Furthermore, physicians' concern is that some people who exhibit milder symptoms of depression are being prescribed drugs unnecessarily due to the lack of other options including talk therapies, counseling and cognitive behavioral therapy. One more factor that may be increasing the consumption of antidepressants is the fact that these medications now are used for other conditions including social anxiety and post traumatic stress.
The use of antidepressants in the US doubled over one decade, from 1996 to 2005. Antidepressant drugs were prescribed to 13 million in 1996 and to 27 million people by 2005. In 2008, more than 164 million prescriptions were written. During this period, patients were less likely to undergo psychotherapy.
Most commonly prescribed
Structural formula of the SSRI escitalopram, in its free base form.
United States: The most commonly prescribed antidepressants in the US retail market in 2010 were:
MAOIs can be as effective as tricyclic antidepressants, although they generally are used less frequently because they have a higher incidence of dangerous side effects and interactions.
2012 GlaxoSmithKline 3 billion dollars (US) - Paxil, The company touted Paxil for off-label use in children and adolescents, despite data that failed to show it was effective for these age groups, – Wellbutrin for marketing its antidepressant for off-label uses, including weight loss, substance abuse and sexual dysfunction and the seizure drug Lamictal.
2012 Johnson & Johnson $1.6 and $2.2 billion Risperdal off-label marketing
2012 Abbott Laboratories $698 million for off-label marketing Depakote for use in dementia patients who became agitated or aggressive, despite lack of evidence that the drug was effective for that use.
2009 Eli Lilly $1.4 billion for marketing Zyprexa for children and the elderly dementia patients, both off-label uses. It is only approved to treat two disorders, schizophrenia and bipolar disorder.
2010 AstraZeneca $520 million for off-label marketing of Seroquel.
2009 Pfizer $301 million for off-label marketing of Geodon.
2007 Bristol-Myers Squibb $515 million for off-label marketing of Abilify for children and adolescents, and geriatric patients suffering from dememtia.
Ely Lilly In one of the only three cases to ever go to trial for SSRI indication in suicide, Eli Lilly and Company was caught corrupting the judicial process by making a deal with the plaintiff's attorney to throw the case, in part by not disclosing damaging evidence to the jury. The case, known as the Fentress Case, involved a Kentucky man, Joseph Wesbecker, on Prozac, who went to his workplace and opened fire with an assault rifle, killing 8 people (including Fentress), and injuring 12 others before turning the gun on himself. The jury returned a 9-to-3 verdict in favor of Lilly. The judge, in the end, took the matter to the Kentucky Supreme Court, which found that "there was a serious lack of candor with the trial court and there may have been deception, bad faith conduct, abuse of judicial process and, perhaps even fraud." The judge later revoked the verdict and instead recorded the case as settled. The value of the secret settlement deal has never been disclosed, but was reportedly "tremendous".
Publication of research findings
Ghost writing of studies for industry-sponsored drug trials is common. Of all 44 trials approved between 1994 and 1995 by the ethics committees of Copenhagen and Frederiksberg in Denmark, up to 91%, that is 40 of the 44 trials, has some form of ghostwriting, and for the most part, the ghost was a statistician. Cases relating to gabapentin, paroxetine, sertraline, fenfluramine/phentermine (fen-phen) are well documented, while many others, relating to olanzapine, quetiapine, remain under seal by the courts.[medical citation needed]
Publication bias. Trials for which results were unfavorable were less likely to be published. Published data suggest a favorable risk-benefit profile for some SSRIs; however, addition of unpublished data indicates that risks could outweigh benefits of these drugs to treat depression in children and young people. Of 90 drugs approved by the FDA between 1998 and 2000, trials that did not show statistically significant results were 34% less likely to have been published; on the other hand, positive results are often published more than once. Based on Healy's examination of the data produced from the Cochrane study of Olanzapine for schizophrenia, the four initial trials of Zyprexa gave rise to 234 publications, most of which were ghost written.
Lack of access to raw data, data suppression, misrepresentation, and manipulation has eroded value of trial results. Demands on access to data has been met by resistance on the part of industry.
A meta-analysis by UK, US and Canadian researchers was published in 2008, surveying all pharmaceutical company-sponsored drug trials on the six most widely prescribed new-generation antidepressants submitted for approval to the FDA between 1987 and 1999. The results showed that the difference in efficacy between antidepressants and placebo was minimal, but that it increased from virtually no difference at moderate levels of initial depression to a relatively small difference for patients with very severe depression. The difference reached conventional criteria for clinical significance for patients at the upper end of the very severely depressed category, due to a reduction in the efficacy of placebo. The study received widespread media coverage in some countries, but was met with criticism from the professional community.
Eli Lilly and Company responded by highlighting that the study did not take into account more recent studies on its product, Prozac, and that it was proud of the difference Prozac has made to millions of people. GlaxoSmithKline warned that this one study should not be used to cause unnecessary alarm and concern for patients. Two leading UK psychiatrists/pharmacologists, with financial and professional links to pharmaceutical companies, argued that short-term approval trials are not very suitable for evaluating effectiveness, that the unpublished trials are of poorer quality, that the meta-analysis authors came from a "psychology background" rather than drug testing background, and that the media and "elements of the medico/scientific community [sic]" have "a down on antidepressants" and that the media do not appreciate the seriousness of depression, and blame and stigmatize sufferers.Wyeth pointed out that the data were good enough for FDA approval of the drugs.
^Fava, M; Rush, AJ; Wisniewski, SR; Nierenberg, AA; Alpert, JE; McGrath, PJ; Thase, ME; Warden, D; Biggs, M et al. (2006). "A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report". The American Journal of Psychiatry163 (7): 1161–72. doi:10.1176/appi.ajp.163.7.1161. PMID16816220.
^ abTrivedi, MH; Fava, M; Wisniewski, SR; Thase, ME; Quitkin, F; Warden, D; Ritz, L; Nierenberg, AA; Lebowitz, BD et al. (2006). "Medication Augmentation after the Failure of SSRIs for Depression". New England Journal of Medicine354 (12): 1243–52. doi:10.1056/NEJMoa052964. PMID16554526.
^Trivedi, MH; Rush, AJ; Wisniewski, SR; Nierenberg, AA; Warden, D; Ritz, L; Norquist, G; Howland, RH; Lebowitz, B et al. (2006). "Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice". American Journal of Psychiatry163 (1): 28–40. doi:10.1176/appi.ajp.163.1.28. PMID16390886.
^Rush, AJ; Trivedi, MH; Wisniewski, SR; Stewart, JW; Nierenberg, AA; Thase, ME; Ritz, L; Biggs, MM; Warden, D et al. (2006). "Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression". New England Journal of Medicine354 (12): 1231–42. doi:10.1056/NEJMoa052963. PMID16554525.
^Warden, D; Rush, AJ; Trivedi, MH; Fava, M; Wisniewski, SR (2007). "The STAR*D Project results: A comprehensive review of findings". Current psychiatry reports9 (6): 449–59. doi:10.1007/s11920-007-0061-3. PMID18221624.
^Baghai, Thomas; Möller, Hans-Jurgen; Rupprecht, Rainer (2006). "Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression". Current Pharmaceutical Design12 (4): 503–15. doi:10.2174/138161206775474422. PMID16472142.
^ abRuhé, HG; Huyser, J; Swinkels, JA; Schene, AH (2006). "Switching Antidepressants After a First Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder". The Journal of Clinical Psychiatry67 (12): 1836–55. doi:10.4088/JCP.v67n1203. PMID17194261.
^Byrne, SE; Rothschild, AJ (1998). "Loss of Antidepressant Efficacy During Maintenance Therapy". The Journal of Clinical Psychiatry59 (6): 279–88. doi:10.4088/JCP.v59n0602. PMID9671339.
^Mischoulon, D; Nierenberg, AA; Kizilbash, L; Rosenbaum, JF; Fava, M (2000). "Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: A survey of clinicians". Canadian journal of psychiatry45 (5): 476–81. PMID10900529.
^Bschor, T; Baethge, C (2010). "No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy". Acta Psychiatrica Scandinavica121 (3): 174–9. doi:10.1111/j.1600-0447.2009.01458.x. PMID19703121.
^Lam, RW; Wan, DDC; Cohen, NL; Kennedy, SH (2002). "Combining Antidepressants for Treatment-Resistant Depression". The Journal of Clinical Psychiatry63 (8): 685–93. doi:10.4088/JCP.v63n0805. PMID12197448.
^Chouinard, G; Chouinard, Virginie-Anne (2008). "Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes". Psychotherapy and Psychosomatics77 (2): 69–77. doi:10.1159/000112883. PMID18230939.
^Geddes, JR; Carney, SM; Davies, C; Furukawa, TA; Kupfer, DJ; Frank, E; Goodwin, GM (2003). "Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review". The Lancet361 (9358): 653–61. doi:10.1016/S0140-6736(03)12599-8. PMID12606176.
^Gardarsdottir, H; Van Geffen, ECG; Stolker, JJ; Egberts, TCG; Heerdink, ER (2009). "Does the Length of the First Antidepressant Treatment Episode Influence Risk and Time to a Second Episode?". Journal of Clinical Psychopharmacology29 (1): 69–72. doi:10.1097/JCP.0b013e31819302b1. PMID19142111.
^ abFava, Giovanni A.; Offidani, Emanuela (2011). "The mechanisms of tolerance in antidepressant action". Progress in Neuro-Psychopharmacology and Biological Psychiatry35 (7): 1593–602. doi:10.1016/j.pnpbp.2010.07.026. PMID20728491.
^ abTurner, EH; Matthews, AM; Linardatos, E; Tell, RA; Rosenthal, R (2008). "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy". New England Journal of Medicine358 (3): 252–60. doi:10.1056/NEJMsa065779. PMID18199864.
^Kirsch, I; Moore, TJ; Scoboria, A; Nicholls, SS (2002). "The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration". Prevention & Treatment5. doi:10.1037/1522-37188.8.131.523a.
^Walsh, BT; Seidman, SN; Sysko, R; Gould, M (2002). "Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing". JAMA287 (14): 1840–7. doi:10.1001/jama.287.14.1840. PMID11939870.
^"Depression in Adults (update)" (PDF). National Collaborating Centre for Mental Health Commissioned by the National Institute for Health and Clinical Excellence. www.nice.org.uk. pp. 282–292. Retrieved 20 November 2013.
^ abcdefghijBrunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (in English) (12th ed.). New York: McGraw-Hill Professional. ISBN978-0-07-162442-8.edit
^ abcdefghRossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN978-0-9805790-9-3.edit
^ abvan Moffaert, M; de Wilde, J; Vereecken, A; Dierick, M; Evrard, JL; Wilmotte, J; Mendlewicz, J (March 1995). "Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression". Int Clin Psychopharmacol10 (1): 3?9. doi:10.1097/00004850-199503000-00001. PMID7622801.
^Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW; van Hulst, AM; van der Mast, RC; van de Wetering, BJ (October 1996). "A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients". Psychopharmacology (Berl.)127 (3): 231?7. doi:10.1007/BF02246131. PMID8912401.
^Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW (May 1999). "Depressed in-patients respond differently to imipramine and mirtazapine". Pharmacopsychiatry32 (3): 87?92. doi:10.1055/s-2007-979200. PMID10463374.
^Louik, C; Lin, AE; Werler, MM; Hernández-Díaz, Sonia; Mitchell, Allen A. (2007). "First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects". New England Journal of Medicine356 (26): 2675–83. doi:10.1056/NEJMoa067407. PMID17596601.
^Pedersen, L H.; Henriksen, T B.; Olsen, J (2010). "Fetal Exposure to Antidepressants and Normal Milestone Development at 6 and 19 Months of Age". Pediatrics125 (3): e600–8. doi:10.1542/peds.2008-3655. PMID20176667.
^Sivagnanam, G (2012). "Antidepressants". Journal of Pharmacology and Pharmacotherapeutics3 (3): 287–8.
^Cox, G. R.; Callahan, P.; Churchill, R.; Hunot, V.; Merry, S. N.; Parker, A. G.; Hetrick, S. E. (2012). "Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents". In Cox, Georgina R. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD008324.pub2.edit
^Friedman, R. A.; Leon, A. C. (2007). "Expanding the Black Box — Depression, Antidepressants, and the Risk of Suicide". New England Journal of Medicine356 (23): 2343–2346. doi:10.1056/NEJMp078015. PMID17485726.edit
^Potenza, edited by Jon E. Grant, Marc N. (2012). The Oxford handbook of impulse control disorders. Oxford: Oxford University Press. ISBN9780195389715.
^Csoka, AB; Bahrick, A; Mehtonen, OP (2008 Jan). "Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors.". The journal of sexual medicine5 (1): 227–33. PMID18173768.Cite uses deprecated parameters (help);Check date values in: |date= (help)
^Montejo, AL; Llorca, G; Izquierdo, JA; Rico-Villademoros, F (2001). "Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction". The Journal of clinical psychiatry62 (Suppl 3): 10–21. PMID11229449.
^Ozmenler, NK; Karlidere, T; Bozkurt, A; Yetkin, S; Doruk, A; Sutcigil, L; Cansever, A; Uzun, O; Ozgen, F et al. (2008). "Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors". Human Psychopharmacology: Clinical and Experimental23 (4): 321. doi:10.1002/hup.929.
^Labbate, LA; Grimes, JB; Hines, A; Pollack, MH (1997 Dec). "Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.". Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists9 (4): 241–5. PMID9511948.Cite uses deprecated parameters (help);Check date values in: |date= (help)
^Ott, GE; Rao, U; Lin, KM; Gertsik, L; Poland, RE (2004 Sep). "Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response.". The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)7 (3): 275–81. PMID15122973.Cite uses deprecated parameters (help);Check date values in: |date= (help)
^Vertes, Robert P.; Eastman, Kathleen E. (2000). "The case against memory consolidation in REM sleep". Behavioral and Brain Sciences23 (6): 867–76; discussion 904–1121. doi:10.1017/S0140525X00004003. PMID11515146.
^Nielsen, Margrethe; Hansen, Ebba Holme; Gøtzsche, Peter C. (2012). "What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors". Addiction107 (5): 900–8. doi:10.1111/j.1360-0443.2011.03686.x. PMID21992148.
^Medawar, C (2004). Medicines out of Control. The Netherlands: Aksant.[page needed]
^ ab"Depressive Disorders". Merck Manual Online. Retrieved 9 January 2014. "Continued therapy with an antidepressant for 6 to 12 mo (up to 2 yr in patients > 50) is usually needed to prevent relapse. Most antidepressants, especially SSRIs, should be tapered off (by decreasing the dose by about 25%/wk) rather than stopped abruptly; stopping SSRIs abruptly may result in discontinuationsyndrome [sic] (nausea, chills, muscles aches, dizziness, anxiety, irritability, insomnia, fatigue). The likelihood and severity of withdrawal varies inversely with the half-life of the SSRI."[not in citation given]
^Valuck, Robert J.; Orton, Heather D.; Libby, Anne M. (2009). "Antidepressant Discontinuation and Risk of Suicide Attempt". The Journal of Clinical Psychiatry70 (8): 1069–77. doi:10.4088/JCP.08m04943. PMID19758520.
^Fava, Giovanni A.; Bernardi, Manuela; Tomba, Elena; Rafanelli, Chiara (2007). "Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia". The International Journal of Neuropsychopharmacology10 (6): 835–8. doi:10.1017/S1461145706007462. PMID17224089.
^Fava, M; Mulroy, R; Alpert, J; Nierenberg, AA; Rosenbaum, JF (1997). "Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine". The American Journal of Psychiatry154 (12): 1760–2. PMID9396960.
^Parker, Gordon; Blennerhassett, Jenny (1998). "Withdrawal reactions associated with venlafaxine". Australian and New Zealand Journal of Psychiatry32 (2): 291–4. doi:10.3109/00048679809062742. PMID9588310.
^Van Noorden, MS; Vergouwen, AC; Koerselman, GF (2002). "Delirium during withdrawal of venlafaxine". Nederlands tijdschrift voor geneeskunde146 (26): 1236–7. PMID12132141.
^Nissen, C; Feige, B; Nofzinger, E; Riemann, D; Berger, M; Voderholzer, U (2005). "Transient narcolepsy-cataplexy syndrome after discontinuation of the antidepressant venlafaxine". Journal of Sleep Research14 (2): 207–8. doi:10.1111/j.1365-2869.2005.00447.x. PMID15910521.
^Agelink, MW; Zitzelsberger, A; Klieser, E (1997). "Withdrawal syndrome after discontinuation of venlafaxine". The American Journal of Psychiatry154 (10): 1473–4. PMID9326838.
^ abMaes, M; Yirmyia, R; Noraberg, J; Brene, S; Hibbeln, J; Perini, G; Kubera, M; Bob, P; Lerer, B; Maj, M (March 2009). "The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression". Metabolic Brain Disease24 (1): 27–53. doi:10.1007/s11011-008-9118-1. PMID19085093.</ref> edit
^Bauer, M; Dopfmer, S (October 1999). "Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies". Journal of Clinical Psychopharmacology19 (5): 427–434. doi:10.1097/00004714-199910000-00006. PMID10505584.
^Aronson, R; Offman, HJ; Joffe, RT; Naylor, CD (September 1996). "Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis". Archives of General Psychiatry53 (9): 842–848. doi:10.1001/archpsyc.1996.01830090090013. PMID8792761.
^Zarate CA, Singh JB, Carlson PJ, et al. (August 2006). "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression". Archives of General Psychiatry63 (8): 856–64. doi:10.1001/archpsyc.63.8.856. PMID16894061.
^Koike, H.; Iijima, M.; Chaki, S. (2011). "Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression". Behavioural Brain Research224 (1): 107–111. doi:10.1016/j.bbr.2011.05.035. PMID21669235. edit
^Nemets, H; Nemets, B; Apter, A; Bracha, Z; Belmaker, RH (2006). "Omega-3 Treatment of Childhood Depression: A Controlled, Double-Blind Pilot Study". American Journal of Psychiatry163 (6): 1098–100. doi:10.1176/appi.ajp.163.6.1098. PMID16741212.
^Sontrop, Jessica; Campbell, M Karen (2006). "Ω-3 polyunsaturated fatty acids and depression: A review of the evidence and a methodological critique". Preventive Medicine42 (1): 4–13. doi:10.1016/j.ypmed.2005.11.005. PMID16337677.
^Rocha Araujo, Daniele Marano; Vilarim, Marina Machado; Nardi, Antonio E (2010). "What is the effectiveness of the use of polyunsaturated fatty acid omega-3 in the treatment of depression?". Expert Review of Neurotherapeutics10 (7): 1117–29. doi:10.1586/ern.10.77. PMID20586692.
^Czygan, Franz-C. (2003). "Kulturgeschichte und Mystik des Johanniskrauts: Vom 2500 Jahre alten Apotropaikum zum aktuellen Antidepressivum" [From a 2500 year old apotropic comes a current antidepressive. The cultural history and mistique of St. John's wort]. Pharmazie in unserer Zeit (in German) 32 (3): 184–90. doi:10.1002/pauz.200390062. PMID12784538.
^Selikoff, Irving J.; Robitzek, EH (1952). "Tuberculosis Chemotherapy with Hydrazine Derivatives of Isonicotinic Acid". CHEST Journal21 (4): 385–438. doi:10.1378/chest.21.4.385. PMID14906149.
^Healy, David (1996). The psychopharmacologists: interviews. London: Chapman and Hall. p. 8. ISBN978-1-86036-008-4.
^Healy, David (1998). The Psychopharmacologists: Volume 2. A Hodder Arnold Publication. pp. 132–4. ISBN978-1-86036-010-7.
^Robitzek, EH; Selikoff, IJ; Mamlok, E; Tendlau, A (1953). "Isoniazid and Its Isopropyl Derivative in the Therapy of Tuberculosis in Humans: Comparative Therapeutic and Toxicologic Properties". CHEST Journal23 (1): 1–15. doi:10.1378/chest.23.1.1. PMID12998444.
^Nathan, P J. (2001). "Hypericum perforatum (St John's Wort): A non-selective reuptake inhibitor? A review of the recent advances in its pharmacology". Journal of Psychopharmacology15 (1): 47–54. doi:10.1177/026988110101500109. PMID11277608.
^(National Institute for Clinical Excellence, 2004)
^Raymond, CB; Morgan, SG; Caetano, PA (2007). "Antidepressant Utilization in British Columbia from 1996 to 2004: Increasing Prevalence but Not Incidence". Psychiatric Services58 (1): 79–84. doi:10.1176/appi.ps.58.1.79. PMID17215416.
^Meijer, WEE; Heerdink, ER; Leufkens, HGM; Herings, RMC; Egberts, ACG; Nolen, WA (2004). "Incidence and determinants of long-term use of antidepressants". European Journal of Clinical Pharmacology60 (1): 57–61. doi:10.1007/s00228-004-0726-3. PMID14985889.
^Zimmerman, M; Posternak, M; Friedman, M; Attiullah, N; Baymiller, S; Boland, R; Berlowitz, S; Rahman, S; Uy, K et al. (2004). "Which Factors Influence Psychiatrists' Selection of Antidepressants?". American Journal of Psychiatry161 (7): 1285–9. doi:10.1176/appi.ajp.161.7.1285. PMID15229063.
^Petersen, T; Dording, C; Neault, NB; Kornbluh, R; Alpert, JE; Nierenberg, AA; Rosenbaum, JF; Fava, M (2002). "A survey of prescribing practices in the treatment of depression". Progress in Neuro-Psychopharmacology and Biological Psychiatry26 (1): 177–87. doi:10.1016/S0278-5846(01)00250-0. PMID11853110.
^Barbui, C; Hotopf, M; Freemantle, N; Boynton, J; Churchill, R; Eccles, MP; Geddes, JR; Hardy, R; Lewis, G et al. (2000). "Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)". In Barbui, Corrado. Cochrane Database of Systematic Reviews (3): CD002791. doi:10.1002/14651858.CD002791. PMID17636706.[unreliable medical source?]
Parker, G; Roy, K; Wilhelm, K; Mitchell, P (2001). "Assessing the Comparative Effectiveness of Antidepressant Therapies". The Journal of Clinical Psychiatry62 (2): 117–25. doi:10.4088/JCP.v62n0209. PMID11247097.
Anderson, IM (2000). "Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability". Journal of Affective Disorders58 (1): 19–36. doi:10.1016/S0165-0327(99)00092-0. PMID10760555.
Lotufo-Neto, F; Trivedi, M; Thase, ME (1999). "Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type a Moclobemide and Brofaromine for the Treatment of Depression". Neuropsychopharmacology20 (3): 226–47. doi:10.1016/S0893-133X(98)00075-X. PMID10063483.